← Back to all trials
Active Not Recruiting
NCT05727423
Dapagliflozin in the Treatment of Heart Failure
Conditions: Heart Failure
Sex: All
Ages: 19 Years – 75 Years
Enrollment: 45
Sponsor: Helwan University
Location: Egypt
Summary
prospectively evaluation the safety and efficacy of the Sodium-glucose Cotransporter-2 (SGLT2) inhibitor dapagliflozin in non-diabetic patients with heart failure and a reduced ejection fraction
Eligibility Criteria
Inclusion Criteria:patients age > 18 yearsDiagnosis of heart failure NYHA class II- IVLVEF ≤ 40% on echocardiographyExclusion Criteria:Estimated glomerular filtration rate <30 ml/min/1.73m2Pregnant or lactating women
Source: ClinicalTrials.gov (NCT05727423). StuddyBuddy aggregates publicly available trial information.
